Encompass Health (EHC) Q3 2026 Earnings Call Transcript
Encompass Health (EHC) reported Q3 2026 revenue growth of 8.9%, adjusted EBITDA up 15.5%, and adjusted EPS up 23.6%. The company raised its 2026 guidance and highlighted strong patient outcomes and industry recognition. It opened new hospitals and added beds, with a pipeline of 15 new hospitals. Q3 bad debt expense was 2.7%, expected to normalize. Adjusted EBITDA was $346.6 million, with net provider tax contribution revised to $3 million for 2026.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise could attract momentum traders and healthcare-focused funds.
Market read
EHC's strong Q3 results and raised outlook provide a clear short‑term trading catalyst.
What to watch
Potential headwinds from Medicaid reimbursement uncertainty and pending CMS approval for Florida program.
Background
Encompass Health is a leading provider of inpatient rehabilitation services in the U.S.
Ticker impact
Q3 2026 earnings released with 8.9% revenue growth, 15.5% adjusted EBITDA increase and raised full-year guidance.
likely upward pressure as investors price in higher revenue and EBITDA guidance.
The company posted better-than-expected financials and lifted guidance, a classic catalyst for short-term price appreciation.
Market effects
Reinforces strength of the inpatient rehabilitation sector and may lift peers.
Positive for U.S. healthcare stocks, especially those with similar payer mix.
Limited to U.S. healthcare investors; no direct global macro effect.
Counterpoint
If the market has already priced in the guidance raise, the stock may face a short‑term pull‑back.
Key entities
- ExecutiveMark Tarr
President and CEO who presented the earnings call.
